COVID-19: Urgent Reconsideration of Lung Edema as a Preventable Outcome: Inhibition of TRPV4 As a Promising and Feasible Approach

摘要: Lethality of Covid-19 during the 2020 pandemic, currently in exponentially-accelerating phase most countries, is critically driven by disruption alveolo-capillary barrier lung, leading to lung edema as a direct consequence SARS-CoV-2 infection We argue for inhibition TRPV4 calcium-permeable ion channel strategy address this issue, based on rationale that protective various preclinical models edema, and hyperactivation potently damages barrier, with lethal outcome believe has powerful prospect at protecting vital patients, even rescue damaged A clinical trial using selective inhibitor demonstrated benign safety profile healthy volunteers patients suffering from cardiogenic expeditious testing respiratory malfunction risk note among pursued therapeutic strategies against Covid-19, none designed directly protect Successful protection will not only reduce lethality but pre-empt catastrophic scenario healthcare insufficient capacity provide ventilator-assisted respiration